Notably, several reports describe the increased risk for euglycemic DKA in individuals with diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors and KD (140, 141). The gene discussed is SLC5A2; the disease is diabetes mellitus.